Skip to main content
Donate

Industry

News

Important update on alogabat, an investigational therapy in development for Angelman syndrome

Today, we are sharing a disappointing update from the Roche/Genentech regarding the discontinuation of the alogabat program for Angelman syndrome. We encourage you to read the full letter from Roche/Genentech for additional information and context.

Thank you to everyone who participated in this trial. Your commitment is meaningful and continues to move research forward.

Read the full letter

Related

FAST Leaders to Speak at the CNBC Cures Summit on Patient- and Family-Led Advocacy
An Update on the ION582 clinical development program including HALOS, REVEAL, and CHAMPION Trials
Voice of the Patient Report Submitted: A Powerful Milestone for the Angelman Syndrome Community
FAST × ASA Angelman Syndrome Clinical Trials Webinar: Europe/UK Sites, Eligibility, and How to Join Trials

View All News

Disclaimer

This website contains information for a broad audience and may include information on current and upcoming programs that are not yet approved or accessible The information provided is for general informational purposes only and is not intended as medical advice, diagnosis, or treatment. While FAST strives to provide accurate and up-to-date information, the content on this site may not always reflect the most current research or clinical guidelines. The inclusion of clinical trial information, treatments or specific healthcare providers does not imply endorsement, recommendation or guarantee of safety, efficacy, or availability. Reliance on any information provided by this website is solely at your own risk. FAST disclaims any liability for any errors or omissions in the information provided or for any decisions made based on this information. For personalized medical advice or specific health concerns including participation in any clinical trial, please consult a qualified healthcare professional.